Condition

PD-1 Inhibitors clinical trials and research

As of November 12, 2026, Find a Trial lists 4 PD-1 Inhibitors clinical trials that are recruiting, in China. Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.

Newest PD-1 Inhibitors clinical trials

StudyPhaseWhereStatusRegistered
Ivonescimab in Neoadjuvant NSCLC: Testing a PD-1/VEGF Bi-specific — Beijing, Beijing Municipality Recruiting Jan 22, 2026
Electro-Acupuncture plus PD-1 inhibitors and chemotherapy in advanced NSCLC — Guangzhou, Guangdong and 2 other locations Recruiting Jan 13, 2026
Electroacupuncture plus PD‑1 immunotherapy for advanced non‑small cell lung cancer with ECOG 2 — Tianjin, Tianjin Municipality Recruiting Nov 20, 2025
Electroacupuncture plus PD-1 immunotherapy for older adults with advanced non-small cell lung cancer — Tianjin, Tianjin Municipality Recruiting Jul 25, 2025

All recruiting trials (4)

Related topics

Non-Small Cell Lung CancerElectroacupunctureImmunotherapyNeoadjuvant TherapyIvonescimab

Quick answers

How many PD-1 Inhibitors clinical trials are recruiting right now?

4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →

Last reviewed 2026-11-12 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.